Navigation Links
Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
Date:10/23/2007

rst of a novel class of therapeutic products engineered to target, attack and eradicate cancers.

For more information about Jennerex, please visit http://www.jennerex.com.

About Green Cross Corporation

Green Cross is a leader in the Korean biotechnology and pharmaceutical industries. Green Cross is now an internationally recognized biotechnology company developing several vaccines and therapeutic proteins. Green Cross will become the only seasonal influenza vaccine manufacturer in South Korea and also is developing avian influenza vaccine. In its vaccine business, Green Cross has successfully developed one of the earliest vaccines against Hepatitis B (Hepavax), the first Epidemic Hemorrhagic Fever vaccine and the world's second chicken pox vaccine. Green Cross is developing anticancer drugs such as Greenstatin (anti-angiogenic peptide) and modified PEG-G-CSF for neutropenia. For more information about Green Cross, please visit http://www.greencross.com.

Contact:

Jennerex Biotherapeutics

Ian W. Malone

Chief Financial Officer

Office: 613-730-8019

Mobile: 613-612-8019

Email: imalone@jennerex.com


'/>"/>
SOURCE Jennerex Biotherapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. Pharmexa A/S (DK) - Pharmexa presents data from influenza program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... (Nasdaq: ERES ) announced today that it will ... May 2, after the market closes. After the release, the ... that day. For the conference call, interested ... or 1-412-858-4600 when calling internationally. There will be a playback ...
... April 15, 2011 Atrium Medical Corporation has provided ... Atrium University, at www.AtriumU.com .  "Atrium has been ... for our customers," said Jeff McGill, Senior Vice President ... guidelines for companies, interactions with nurses and physicians, we ...
Cached Medicine Technology:ERT Reports First Quarter 2011 Operating Results on May 2, 2011 2Atrium Provides Grant to Establish Education Web Site at AtriumU.com 2
(Date:4/18/2014)... your worst memories? How did it make you feel? ... negative personal experience, such as how sad you were ... distress, especially when you can,t stop thinking about it. ... about the context of the memories, rather than how ... to alleviate the negative effects of these memories, a ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... A series of new guidelines for cardiac specialists has ... receive a mechanical heart-pumping device. "The new guidelines ... circulatory support device, and how early in the process ... device," says Jeffrey A. Morgan, M.D., associate director of ...
... 15 (HealthDay News) -- U.S. scientists who completed the ... will improve the ability to diagnose and treat the ... an approach that decodes the 1 to 2 percent ... team, led by researchers at the U.S. National Institutes ...
... Kobe City University of Foreign Studies surveyed and questioned Twitter ... on the social media site two weeks after the Tohoku ... determine what benefits such a system can bring to people ... news. The researchers found that people in directly affected ...
... Meat and poultry sold in the United States is widely ... bacteria that can cause serious illnesses in humans, a new ... to S. aureus range from mild skin infections ... In the new nationwide study, researchers analyzed 136 samples ...
... FRIDAY, April 15 (HealthDay News) -- Teens who start school ... crashes, a new study finds. But starting the school ... reduce impulsiveness, another study finds. In 2008, the weekday ... Va., was about 41 percent higher than for the same ...
... when occurring with hay fever, are nine times more likely ... reveals. The study was conducted by the University ... and Monash University. Published online in the ... reported on evidence from a clinical study of around 1400 ...
Cached Medicine News:Health News:Scientists Spot Key Gene Mutations in Melanoma 2Health News:Twitter and natural disasters 2Health News:Twitter and natural disasters 3Health News:Drug-Resistant Staph Bacteria Found in Meat, Poultry Nationwide 2Health News:Drug-Resistant Staph Bacteria Found in Meat, Poultry Nationwide 3Health News:Early School Start Tied to More Teen Crashes: Study 2Health News:Childhood eczema and hay fever leads to adult allergic asthma 2
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
... Millipore has developed a range ... to match specific water quality requirements. ... systems is designed to specifically target ... as HPLC, molecular biology and ICP-MS. ...
... Bridge assembly allows internal or ... cooling coil allows rapid cool-down ... within approximately 10 C of ... is only 5.7 inches wideideal ...
Inquire...
Medicine Products: